The FDA said it could not approve poziotinib to treat non-small cell lung cancer, and if Spectrum wanted to resubmit an application it would need more data and a randomized study, the drugmaker said in a Nov. 28 news release. In response, Spectrum said it will deprioritize the poziotinib program, effective immediately.
The biopharmaceutical company said the 75 percent reduction in its R&D workforce will “generate the working capital required to support its strategic refocusing through 2024.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.